Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Revolution Medicines, Inc.”

32 pharma patents match "Revolution Medicines, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "Revolution Medicines, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “Revolution Medicines, Inc.” · 30,257 patents in full index Clear search

  1. US 11220501

    Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor

    Revolution Medicines, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  2. US 11168102

    Bicyclic heteroaryl compounds and uses thereof

    Revolution Medicines, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  3. US 11059830

    Compounds that participate in cooperative binding and uses thereof

    Revolution Medicines, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  4. US 10980889

    C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  5. US 10948495

    Methods and reagents for analyzing protein-protein interfaces

    Revolution Medicines, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  6. US 10590090

    2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  7. US 10533016

    Compounds that participate in cooperative binding and uses thereof

    Revolution Medicines, Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  8. US 10466249

    Methods and reagents for analyzing protein-protein interfaces

    Revolution Medicines, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted